BUDAPEST (Reuters) - Hungarian drug maker Richter and its partner Actavis on Tuesday said a Phase III trial had positive results in anti-psychotic drug Cariprazine's effects to prevent relapse for schizophrenia patients. Treatment with Cariprazine was associated with a 55 percent reduction in the risk of relapse versus placebo, the companies said in a statement posted on the Budapest Stock Exchange web site.
About
Social Profiles
-
Nurse Kaci Hickox (L) joined by her boyfriend Ted Wilbur speak with the media outside of their home in Fort Kent, Maine Oct...
-
Did you know approximately nine in ten people will catch chickenpox if they haven’t been vaccinated against it? ...
-
Background Metabolic syndrome (MetSyn) increases the incidence of cardiovascular disease. Information on changes in p...
-
Background As the most popular video sharing website in the world, YouTube has the potential to reach and influence a...
-
New Year Health Tips Today, I am going to share few of the very interesting articles on New year healt...
-
Did you know approximately nine in ten people will catch chickenpox if they haven’t been vaccinated against it? ...
-
Background The prevalence of childhood overweight and obesity in developed countries appears to be levelling off. As ...
-
Background Little is known about preschool parents’ cognitions, barriers, supports and modeling of key obesogenic beh...
-
A medical staff holds a package of an experimental candidate vaccine rVSV-ZEBOV against Ebola virus disease at the Universi...
-
Background The dramatic growth of mobile phone (MP) use among young people has increased interest in its possible hea...